Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report

A 28-year-old woman with autosomal dominant familial hypercholesterolemia (FH) with a probable coexistent polygenic contribution causing very high low-density lipoprotein-cholesterol (LDL-C) levels, started therapy with the proprotein convertase subtilisin/kexin type 9-inhibitor (PCSK9i) alirocumab,...

Full description

Bibliographic Details
Main Authors: Massimiliano Allevi, Silvia Sarnari, Federico Giulietti, Francesco Spannella, Chiara Di Pentima, Riccardo Sarzani
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
familial hypercholesterolemia
polygenic hypercholesterolemia
injection site reaction
PCSK9-Inhibitor
inclisiran
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1181720/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1181720/full

Similar Items